Search filters

List of works by Jorge Eduardo Cortes

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

scientific article

2008. Effective and Early Diagnosis of Pneumonia in Patients With Acute Leukemia in a Comprehensive Cancer Center: How Can We Improve the Microbiological Diagnosis?

6 Natural history and staging of chronic myelogenous leukaemia ⬇️

scientific article published on June 1, 1997

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

scientific article

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

scientific article published on 27 February 2015

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

scientific article published on 12 September 2017

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

scientific article published on 21 December 2015

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

scientific article published on 02 August 2018

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.

scientific article

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

scientific article published in April 2004

A heavy metal baseline score predicts outcome in acute myeloid leukemia

journal article published in 2020

A journey searching for a cure for leukemia. Interviewed by Natasha Galukande

scientific article published in June 2013

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia

scientific article published on 6 July 2013

A multinational study of health state preference values associated with chronic myelogenous leukemia

scientific article published on 29 July 2009

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

scientific article

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

scientific article

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

scientific article

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

scientific article published on 05 September 2018

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

scientific article

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis

scientific article

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

scientific article published on 19 April 2008

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat

scientific article published on 17 April 2015

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

scientific article published in August 2002

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

scientific article

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

scientific article published on 14 June 2017

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

scientific article

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.

scientific article

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

scientific article published on 18 July 2017

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia

scientific article

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

scientific article

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities

scientific article

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

scientific article

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

scientific article published in February 2007

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

scientific article

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

scientific article

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

scientific article published on 10 August 2016

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors

scientific article published on 14 October 2018

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

scientific article

A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.

scientific article

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

scientific article

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission ⬇️

scientific article published on 05 June 2012

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

scientific article

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

scientific article published in March 2003

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

scientific article

A second-generation TKI should always be used as initial therapy for CML

scholarly article published 26 December 2018

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

scientific article

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

scientific article published on July 2005

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

scientific article

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia

scientific article

Accelerated and blastic phases of chronic myelogenous leukemia

scientific article published in June 2004

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

scientific article published on 18 September 2017

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

scientific article published on 24 April 2012

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors ⬇️

scientific article published on October 28, 2011

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

scientific article published on 8 May 2006

Activity of alemtuzumab in patients with CD52-positive acute leukemia

scientific article published on 01 June 2006

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

scientific article

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis

scientific article

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation

scientific article published on 25 June 2015

Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation

scientific article published on 21 June 2014

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

scientific article published on 24 February 2016

Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.

scientific article

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

scientific article

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

scientific article published in May 2003

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

scientific article published on 11 October 2018

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

scientific article

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

scientific article published on 25 August 2005

Advanced-phase chronic myeloid leukemia

scientific article

Advances in the therapy of chronic idiopathic myelofibrosis

scientific article published on September 2006

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation

scientific article published on 31 March 2015

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

scientific article published in December 2003

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

scientific article published on January 2009

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia

scientific article

Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia

scientific article

Allogeneic hematopoietic cell transplant for prolymphocytic leukemia ⬇️

scientific article

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia

scientific article

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

scientific article published on 7 March 2014

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias

scientific article published on 16 September 2011

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure

scientific article

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

scientific article

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

scientific article published on 26 December 2007

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

scientific article

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

scientific article published on 5 February 2016

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

scientific article

Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia ⬇️

scientific article published on 01 September 1997

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

scientific article published on 23 April 2013

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

scientific article published on 14 September 2017

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen

scientific article published on October 2010

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

scientific article published on 17 January 2017

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

scientific article published in June 2015

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

scientific article published on 01 December 2019

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

scientific article published on 28 June 2013

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

scientific article published on 12 November 2020

Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia ⬇️

scientific article published on 01 April 1998

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.

scientific article published on 20 March 2018

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome

scientific article

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

scientific article

Azacitidine for the treatment of myelodysplastic syndrome

scientific article published on July 2009

Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study

scientific article

BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.

scientific article

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

scientific article

BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias

scientific article published on 22 September 2008

BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival

scientific article published on 14 August 2015

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors

scientific article published on 31 March 2009

BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.

scientific article published on March 2008

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

scientific article

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study

scientific article published on 03 December 2020

Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

scientific article published on December 2010

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

scientific article published on 24 September 2013

Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders

scientific article published on May 2004

Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.

scientific article published on March 2008

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

scientific article

Biology of platelet-derived growth factor and its involvement in disease

scientific article

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

scientific article

Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study

scientific article published on April 2007

Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value

scientific article published on 15 October 2018

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

scientific article published in October 2002

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

scientific article published on 23 January 2013

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

scientific article

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

scientific article published in November 2017

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

scientific article

Bosutinib in the treatment of chronic myelogenous leukemia

scientific article published on November 1, 2012

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

scientific article published on 27 February 2012

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

scientific article published on 17 December 2013

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

scientific article

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

scientific article

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

scientific article

C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome

scientific article published in April 2004

CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias

scientific article

CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis

scientific article

CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes

scientific article

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

scientific article published on 4 January 2016

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

scientific article

CML: the good, the better, and the difficult choices ⬇️

scientific article published on November 8, 2012

CMML: a biologically distinct myeloproliferative disease.

scientific article

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

scientific article published on 19 July 2018

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System

scientific article

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations

scientific article

Cause of death in patients with lower-risk myelodysplastic syndrome

scientific article published on May 2010

Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies

scientific article

Central nervous system relapse in adults with acute lymphoblastic leukemia

scientific article published on February 2002

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations

scientific article published on 20 February 2018

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

scientific article

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

scientific article

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach

scientific article

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

scientific article published on October 2012

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

scientific article

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

scientific article

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment

scientific article published on 17 February 2009

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia

scientific article published on 24 December 2014

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

scientific article published on 22 February 2019

Characteristics of pericardial effusions in patients with leukemia

scientific article published on May 2010

Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia

scientific article

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

scientific article

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

scientific article published on 4 April 2017

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

scientific article

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

scientific article

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

scientific article

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage

scientific article published on 11 October 2018

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents

scientific article

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts

scientific article published on 20 August 2019

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

scientific article published in November 2003

Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis

scientific article

Chromosome 5q deletion is extremely rare in patients with myelofibrosis

scientific article published on 4 February 2013

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment ⬇️

scientific article published on October 19, 2011

Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis ⬇️

scientific article published on June 1, 2013

Chronic myelogenous leukemia: a review and update of therapeutic strategies

scientific article

Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

scientific article published on 16 June 2009

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

scientific article published on 20 October 2016

Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?

scientific article published on October 2010

Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature

scientific article published on June 2004

Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature

scientific article published on 10 September 2014

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?

scientific article published on September 2010

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?

scientific article published on September 2009

Chronic myeloid leukemia: The race is yet to be won ⬇️

scientific article published on January 23, 2012

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

scientific article

Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment

scientific article

Chronic myeloid leukemia: diagnosis and treatment

scientific article published on July 2006

Chronic myeloid leukemia: reminiscences and dreams

scientific article

Chronic myeloid leukemia: sequencing of TKI therapies.

scientific article published on December 2016

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

scientific article

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

scientific article published on 27 April 2018

Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia

scientific article published on 13 May 2019

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

scientific article published in October 2017

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia

scientific article published on 26 July 2017

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

scientific article published on 29 August 2017

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

scientific article published on 18 December 2015

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

scientific article

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

scientific article published on November 2013

Clinical activity of tipifarnib in hematologic malignancies

scientific article published on March 2007

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

scientific article published on 18 January 2017

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

scientific article

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

scientific article published on 14 July 2017

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

scientific article

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

scientific article

Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens

scientific article published on 24 June 2017

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

scientific article published on 29 July 2013

Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).

scientific article published on 11 October 2016

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome

scientific article

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

scientific article

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

scientific article

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.

scientific article

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

scientific article

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 09 February 2016

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

scientific article published in Nature Communications

Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.

scientific article

Clinical significance of microcytosis in patients with primary myelofibrosis

scientific article

Clinical trials have a home in Blood

scientific article published on 01 June 2014

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

scientific article published on 5 August 2016

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

scientific article published on 24 November 2015

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

scientific article published on 10 January 2006

Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

scientific article

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

scientific article

Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment

scientific article published on 23 August 2017

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

scientific article

Clonal evolution in chronic myelogenous leukemia

scientific article published in June 2004

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 21 October 2020

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group

scientific article published on 17 August 2017

Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia

scientific article published on 30 October 2020

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

scientific article published on 29 September 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells

scientific article published on September 2016

Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts ⬇️

scientific article published on December 15, 2001

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation

scientific article

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

scientific article

Competing cell clones in myeloproliferative neoplasm

scientific article published on December 2010

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

scientific article

Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.

scientific article

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

scientific article published in April 2009

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

scientific article

Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

scientific article published on 08 January 2021

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

scientific article published on 12 July 2017

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

scientific article

Congestive heart failure is a rare event in patients receiving imatinib therapy

scientific article

Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

scientific article published on 21 March 2011

Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

scientific article published on 25 November 2019

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study

scientific article published on 16 August 2010

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

scientific article

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study

scientific article published on 5 December 2013

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

scientific article published on 30 May 2017

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

scientific article

Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure ⬇️

scientific article published on October 1, 2012

Current and emerging treatment options in chronic myeloid leukemia

scientific article

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

scientific article

Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).

scientific article published on November 2010

Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment

scientific article

Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

scientific article

Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation

scientific article

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

scientific article

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

scientific article published on 08 December 2017

Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia

scientific article

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion

scientific article

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

scientific article

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias

scientific article published on May 2007

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias ⬇️

scientific article published on September 20, 2012

Dasatinib for the treatment of chronic myeloid leukemia

scientific article

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

scientific article (publication date: 15 June 2006)

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

scientific article published on 19 May 2016

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

scientific article published on August 2010

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

scientific article

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

scientific article published on 21 December 2006

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

scientific article

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations

scientific article published on April 2009

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

scientific article published on 24 September 2009

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 5 June 2010

Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase

scientific article published on 4 April 2011

Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome

scientific article

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson ⬇️

scientific article published on June 13, 2013

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration ⬇️

scientific article published on August 24, 2010

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

scientific article published on 15 April 2009

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.

scientific article published on 2 April 2018

Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia

scientific article

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

scientific article published on 19 October 2015

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

scientific article published on 08 July 2013

Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission

scientific article

Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis

scientific article published on 27 May 2012

Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia

scientific article published on 23 December 2020

Development and targeted use of nilotinib in chronic myeloid leukemia.

scientific article

Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study

scientific article published on 12 September 2019

Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.

scientific article published on October 2015

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

scientific article published on April 2007

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

scientific article published on 06 May 2016

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

scientific article published on 03 February 2017

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia

scientific article published on 7 September 2016

Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia

scientific article published on 29 August 2012

Discontinuation of imatinib therapy after achieving a molecular response

scientific article published in October 2004

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers

scientific article published on 13 November 2013

Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia

scientific article published on 20 February 2018

Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

scientific article

Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

scientific article

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

scientific article published on 12 April 2017

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

scientific article published on 12 September 2002

Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia

scientific article published on 23 May 2013

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

scientific article

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML ⬇️

scientific article published on June 7, 2013

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article published on 28 September 2009

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

scientific article

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib

scientific article published on 12 September 2014

Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells

scientific article published on 8 June 2011

EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience

scientific article

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

scientific article published on 15 August 2006

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

scientific article published on 08 January 2016

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

scientific article

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

scientific article published on 25 April 2013

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

scientific article

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

scientific article

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

scientific article

Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.

scientific article published on 3 July 2003

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

scientific article

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin

scientific article published on 15 December 2008

Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies

scientific article published on 05 October 2014

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

scientific article published on 23 June 2006

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

scientific article published on 17 June 2017

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in September 2003

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

scientific article

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States

scientific article published on 10 September 2019

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

scientific article published on 3 December 2009

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

scientific article published on 27 December 2019

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

scientific article published on February 2009

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

scientific article published on 20 February 2003

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

scientific article published on 31 October 2002

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

scientific article published on 08 November 2018

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia ⬇️

scientific article published on March 22, 2011

Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors

scientific article published on March 2007

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

scientific article published in June 2003

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

scientific article published on 20 October 2009

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

scientific article published on 15 October 2012

Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia

scientific article

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial

scientific article published on 12 July 2011

Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine

scientific article published on 14 December 2012

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

scholarly article published in Cancer

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

scientific article

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

scientific article published on 02 August 2007

Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

scientific article published on 28 July 2015

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

scientific article published on 31 January 2012

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

scientific article published on 26 June 2013

Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study

scientific article published on 16 February 2016

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

scientific article

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.

scientific article

Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia

scientific article published on April 2007

Evolution of Therapies for Chronic Myelogenous Leukemia ⬇️

scientific article published on November 1, 2011

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

scientific article

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy

scientific article

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

scientific article published on 09 January 2003

Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis

scientific article

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

scientific article

Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia

scientific article

Experimental therapeutics for patients with myeloproliferative neoplasias

scientific article published on 04 October 2010

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.

scientific article

FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

scientific article

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

scientific article

Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia

scientific article published on 27 May 2017

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

scientific article published on 4 November 2015

Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast

scientific article

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

scientific article published on 20 May 2008

Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.

scientific article published in May 2004

Farnesyl transferase inhibitor resistance probed by target mutagenesis

scientific article published on 15 September 2007

Farnesyltransferase Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes ⬇️

scientific article published on August 1, 2003

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

scientific article published on 28 August 2003

Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies

scientific article

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

scientific article published on 11 October 2007

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency

scientific article

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

scientific article published on 23 May 2016

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

scientific article published on 13 January 2015

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 14 February 2015

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

scientific article

Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

scientific article

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

scientific article published on 16 April 2018

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

scientific article published on 14 May 2016

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

scientific article

First-line therapy for chronic myeloid leukemia: Past, present, and future

scientific article published on May 2009

First-line treatment for patients with CML in chronic phase: second-generation TKIs are the therapy of choice

scientific article published in August 2013

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

scientific article

Flying under the radar: the new wave of BCR-ABL inhibitors

scientific article published on October 2007

Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome ⬇️

scientific article published on July 1, 2001

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

scientific article published in April 2003

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

scientific article published on 10 January 2011

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

scientific article published on 11 October 2011

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

scientific article published on 12 May 2016

Frontline treatment of acute myeloid leukemia in adults

scientific article published on 11 December 2016

Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

scientific article

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia ⬇️

scientific article published on June 1, 1998

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

scientific article published on 21 July 2014

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

scientific article published in June 2002

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

scientific article

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

scientific article published in March 2003

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

scientific article published on 01 October 2019

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

scientific article published on 09 September 2018

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials

scientific article published on 13 September 2019

Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications ⬇️

scientific article published on March 21, 2013

Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia

scientific article

Granulocytic sarcoma of the pancreas: a report of two cases and literature review

scientific article

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia

scientific article published on 22 October 2013

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

scientific article published on 13 September 2017

Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.

scientific article published on 5 April 2016

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

scientific article published in January 2010

Hedgehog signaling inhibitors in solid and hematological cancers

scientific article published on 06 May 2019

Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

scientific article

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

scientific article published on 31 August 2009

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

scientific article published on 24 December 2003

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

scientific article published on 9 November 2017

Homoharringtonine for the treatment of chronic myelogenous leukemia

scientific article published on April 2008

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

scientific article

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval ⬇️

scientific article published on June 20, 2013

How I treat newly diagnosed chronic phase CML

scientific article published on 21 May 2012

How to manage CML patients with comorbidities?

scientific article published on 25 November 2020

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

scientific article published on 13 December 2010

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

scientific article

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

scientific article published in August 2016

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

scientific article

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients ⬇️

scientific article published on November 4, 2011

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

scientific article published on 24 November 2015

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

scientific article published on 07 August 2019

Imatinib and beyond--exploring the full potential of targeted therapy for CML.

scientific article published on 04 August 2009

Imatinib effect on growth and signal transduction in polycythemia vera

scientific article published on June 2007

Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction

scientific article

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status

scientific article published on 14 November 2008

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

scientific article published in May 2002

Imatinib mesylate causes hypopigmentation in the skin

scientific article published in December 2003

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

scientific article

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

scientific article

Imatinib mesylate in the treatment of chronic myelogenous leukemia

scientific article published in June 2004

Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001

scientific article

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

scientific article

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

scientific article

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

scientific article published on 29 August 2002

Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia

scientific article published on 30 November 2004

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

scientific article published in July 2004

Imatinib therapy for chronic myeloid leukemia: where do we go now?

scientific article published on 2 June 2008

Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

scientific article published in March 2007

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

scientific article

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

scientific article published on 4 January 2016

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

scientific article published on 11 January 2017

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

scientific article published on 03 August 2009

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

scientific article published on 11 July 2013

Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients

scientific article

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia

scientific article

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

scientific article published on 19 November 2019

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

scientific article published on 11 July 2011

Important therapeutic targets in chronic myelogenous leukemia

scientific article published on February 2007

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

scientific article published on 6 January 2012

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

scientific article

Improving attribution of adverse events in oncology clinical trials

scientific article published on 25 April 2019

Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience

scientific article

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

scientific article

Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia

scientific article published on 3 November 2014

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience

scientific article

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

scientific article published on 04 March 2019

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

scientific article published on 3 November 2014

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

scholarly article by Timothy P Hughes et al published January 2019 in Haematologica

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome

scientific article published in May 2003

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities

scientific article published on 2 February 2015

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

scientific article published in March 2003

Influence of IDH on FLT3-ITD status in newly diagnosed AML.

scientific article

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells

scientific article

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia ⬇️

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

scientific article published on 15 April 2019

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

scientific article published on 21 February 2012

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

scientific article published in May 2015

Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

scientific article published in Nature Communications

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

scientific article published on 28 July 2010

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study

scientific article

Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

scientific article

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

scientific article published on 01 June 2005

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

scientific article

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

scientific article

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications

scientific article published on 04 October 2010

Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions

scientific article published on September 2003

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

scientific article published in February 2004

Introduction to a review series on adolescent and young adult malignant hematology

scientific article published on 12 June 2018

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

scientific article

Investigational agents in myeloid disorders

scientific article published in January 2004

Investigational strategies in chronic myelogenous leukemia

scientific article published in June 2004

Is acute myeloid leukemia a liquid tumor? ⬇️

scientific article published on 04 February 2013

Is there a standard induction regimen for patients with AML?

scientific article

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms

scientific article

Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia

scientific article published on 27 February 2019

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

scientific article published on February 2011

Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival

scientific article published on 6 June 2015

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

scientific article published on 28 September 2016

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors

scientific article published on 25 July 2013

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

scientific article

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

scientific article published on 4 February 2014

Late relapses in acute myeloid leukemia: analysis of characteristics and outcome

scientific article

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

scientific article published on 17 June 2019

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

scientific article

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

scientific article

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

scientific article published on 3 October 2017

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial

scientific article published on 14 March 2018

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

scientific article published on January 2003

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

scientific article

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis

scientific article published on 15 March 2018

Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors

scientific article published on June 2015

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

scientific article

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published on 25 September 2019

Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody

scientific article published on November 2012

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

scientific article published in March 2006

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr

scientific article

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

scientific article published on 21 December 2016

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

scientific article

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

scientific article published on 25 February 2014

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

scientific article published on 13 October 2010

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

scientific article

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

scientific article published on 26 October 2017

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

scientific article

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

scientific article

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis

scientific article published on 23 June 2016

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

scientific article

Long-term results of frontline dasatinib in chronic myeloid leukemia

scientific article published on 30 January 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

scientific article published on 14 April 2008

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

scientific article

Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia

scientific article

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

scientific article

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

scientific article published on 21 March 2016

MYC protein expression is an important prognostic factor in acute myeloid leukemia

scientific article published on 09 May 2018

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

scientific article published on 16 August 2011

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

scientific article published on 31 May 2016

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

scholarly article by Jorge Eduardo Cortes et al published 27 December 2018 in Journal of Hematology & Oncology

Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience

scientific article published on 07 December 2020

Management of imatinib-resistant patients with chronic myeloid leukemia ⬇️

scientific article published on April 1, 2013

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

scientific article published on March 2007

Management of patients with resistant or refractory chronic myelogenous leukemia.

scientific article published on April 2008

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

scientific article published in November 2004

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome

scientific article published on 01 June 2017

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

scientific article published on 15 May 2019

Measuring symptoms as a critical component of drug development and evaluation in hematological diseases

scientific article

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

scientific article (publication date: August 2013)

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia

scientific article

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

scientific article

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

scientific article

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

scientific article published on 22 October 2015

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

scientific article published on 11 May 2017

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

scientific article published in April 2003

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

scientific article

Molecular Resistance: An Early Indicator for Treatment Change? ⬇️

scientific article published on January 28, 2012

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a

scientific article published on 19 June 2013

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

scientific article

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

scientific article published on 30 September 2008

Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications

scientific article published on May 2008

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

scientific article

Molecular targeted therapy in acute myeloid leukemia ⬇️

scientific article published on April 1, 2012

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

scientific article published on 7 March 2006

Monitoring molecular response in chronic myeloid leukemia ⬇️

scientific article published on October 19, 2010

Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods

scientific article

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

scientific article

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia

scientific article published on August 2016

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

scientific article published on 03 October 2011

Mutant BCR-ABL clones in chronic myeloid leukemia

scientific article published on March 2011

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

scientific article

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

scientific article

Mutations in AML: prognostic and therapeutic implications

scientific article published on December 2016

Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome

scientific article

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

scientific article published on 29 June 2006

Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor

scientific article

Myelopathy following intrathecal chemotherapy in adults: a single institution experience

scientific article

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

scientific article

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

scientific article published on 9 September 2003

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia

scientific article published on 18 March 2019

Natural history and staging of chronic myelogenous leukemia

scientific article published in June 2004

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents

scientific article published on 26 May 2017

Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series

scientific article published on 27 June 2019

Neutrophilic-chronic myeloid leukemia

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course

scientific article

New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia

scientific article published on 4 July 2017

New agents in acute myeloid leukemia and other myeloid disorders

scientific article published on February 2004

New agents in chronic myelogenous leukemia.

scientific article published on October 2003

New agents in the treatment of acute lymphocytic leukaemia

scientific article

New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia

scientific article published on July 2007

New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

scientific article published on February 2011

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

scientific article published on December 2006

New strategies in chronic myeloid leukemia

scientific article

New targeted approaches in chronic myeloid leukemia

scientific article

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

scientific article published on January 2007

New treatment for acute myelogenous leukemia

scientific article

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

scientific article published on 18 October 2013

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

scientific article

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

scientific article

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia ⬇️

scientific article published on November 13, 2010

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review ⬇️

scientific article published on June 15, 2010

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

scientific article (publication date: 15 June 2006)

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

scientific article

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

scientific article published on 22 November 2010

Nilotinib therapy in chronic myelogenous leukemia

scientific article published on October 2007

Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias

scientific article published in July 2008

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

scientific article published on October 2008

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

scientific article published on 15 April 2004

Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia ⬇️

scientific article published on December 19, 2011

Novel approaches in the treatment of systemic mastocytosis

scientific article published on October 2006

Novel therapies for patients with chronic myeloid leukemia

scientific article published on April 2004

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

scientific article published on 01 July 2007

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia

scientific article published on November 2006

Obesity, weight gain, and risk of chronic myeloid leukemia

scientific article

Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia

scientific article

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

scientific article published on 6 February 2016

Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia

scientific article published on 23 July 2013

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

scientific article published on 10 June 2013

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

scientific article published on 28 April 2014

Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.

scientific article published in May 2008

Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia

scientific article

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

scientific article

Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?

scientific article published on May 2007

Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article published on March 2007

Optimizing first-line therapy for patients with chronic myeloid leukemia.

scientific article published in April 2009

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

scientific article

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia

scientific article published on February 2008

Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase

scientific article published on March 2010

Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

scientific article published on 26 April 2010

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia

scientific article published on 14 June 2013

Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy

scientific article

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

scientific article

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

scientific article published on December 2008

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission

scientific article published on 18 January 2010

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

scientific article published on 29 October 2009

Outcome of patients with acute myelogenous leukemia after second salvage therapy

scientific article published on August 2005

Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

scientific article

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy

scientific article published on August 2010

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

scientific article published on 27 November 2017

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

scientific article

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure

scientific article published on 28 April 2011

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

scientific article

Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation

scientific article

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia

scientific article published on 25 September 2017

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma

scientific article published on 15 March 2017

Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens

scientific article

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

scientific article published on 24 May 2019

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

scientific article published on April 2014

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

scientific article published on 17 January 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

scientific article published on 7 April 2017

Overcoming drug resistance in chronic myeloid leukemia

scientific article

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

scientific article published on 01 November 2007

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

scientific article published on 03 September 2013

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

scientific article published on 22 September 2016

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

scientific article

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

scientific article published on 5 January 2016

Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms

scientific article published on 15 November 2017

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

scientific article

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

scientific article published on 15 April 2019

Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome

scientific article published on 14 August 2013

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

scientific article

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

scientific article

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

scientific article

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

scientific article published on 13 October 2009

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy

scientific article published on 30 July 2016

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation

scientific article published on 09 May 2011

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

scientific article published on 22 September 2016

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

scientific article published on 5 December 2016

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

scientific article published on 17 November 2005

Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia

scientific article

Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

scientific article published on 22 July 2020

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

scientific article

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

scientific article published on 01 September 2005

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

scientific article

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

scientific article

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

scientific article published on 8 August 2012

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

scientific article published on 6 November 2003

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

scientific article

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

scientific article (publication date: 25 October 2007)

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

scientific article

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

scientific article

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

scientific article published in August 2006

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

scientific article published on 14 March 2020

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

scientific article

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

scientific article published on 29 June 2011

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

scientific article

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

scientific article published on 23 April 2013

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

scientific article

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

scientific article

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

scientific article published on 15 March 2012

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

scientific article

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

scholarly article by Farhad Ravandi et al published November 2018 in Haematologica

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

scientific article published on 15 April 2009

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia

scientific article

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

scientific article published in December 2003

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia

scientific article published in July 2002

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

scientific article published in April 2004

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome

scientific article published on 23 November 2009

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

scientific article published in March 2003

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

scientific article published on 11 December 2013

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia

scientific article

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

scientific article

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

scientific article

Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies

scientific article published on 19 February 2015

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

scientific article

Phase I study of bortezomib in refractory or relapsed acute leukemias

scientific article published in May 2004

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

scientific article published on November 2005

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia

scientific article published on 11 May 2016

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

scientific article published on 03 September 2013

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

scientific article

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome

scientific article

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

scientific article published on 18 July 2020

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

scientific article

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

scientific article

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

scientific article published in January 2007

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

scientific article

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

scientific article

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia ⬇️

scientific article published on April 27, 2012

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis

scientific article published on 17 February 2015

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

scientific article published in April 2004

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

scientific article

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

scientific article published on June 2008

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

scientific article

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

scientific article

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

scientific article published on March 2007

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

scientific article published on 9 May 2005

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

scientific article published on 19 November 2014

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

scientific article

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

scientific article published in February 2002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

scientific article published in December 2003

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

scientific article published on 16 June 2020

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

scientific article published on 9 February 2017

Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

scientific article published on March 2014

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor

scientific article published on 4 September 2015

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

scientific article published on 14 May 2012

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

scientific article

Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

scientific article

Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS.

scientific article published on 20 February 2018

Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia

scientific article published on 28 July 2019

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

scientific article published on 21 October 2019

Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia

scientific article published in September 2008

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy

scientific article published on 27 September 2007

Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure ⬇️

scientific article published on November 1, 2001

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

scientific article

Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase

scientific article published on August 2011

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

scientific article

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

scientific article

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

scientific article

Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial

scientific article

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

scientific article published on 17 September 2016

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

article

Pneumonia during remission induction chemotherapy in patients with acute leukemia

scientific article

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

scientific article

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

scientific article published on 22 March 2018

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

scientific article published on 21 May 2013

Ponatinib in refractory Philadelphia chromosome-positive leukemias

scientific article

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

scientific article

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

scientific article published on 22 December 2016

Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid

scientific article published in February 2005

Potential role of sorafenib in the treatment of acute myeloid leukemia

scientific article published on December 2008

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

scientific article

Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia

scientific article published on 12 June 2014

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy

scientific article

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

scientific article published on 20 December 2017

Prediction model for mortality after intracranial hemorrhage in patients with leukemia

scientific article

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

scientific article published on 3 October 2011

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in May 2003

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

scientific article

Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

scientific article

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

scientific article

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

scientific article published on 30 January 2006

Pregnancy in a patient with hypereosinophilic syndrome

scientific article published on July 2008

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia

scientific article published on 15 October 2020

Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System

scientific article published in June 2007

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

scientific article published on 25 July 2017

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

scientific article

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

scientific article

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome

scientific article

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

scientific article published on 01 December 2020

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib

scientific article

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

scientific article published on 21 January 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

scientific article published on 3 October 2016

Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis

scientific article published on 21 February 2013

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

scientific article

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia

scientific article published on 04 February 2013

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

scientific article

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

scientific article

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

scientific article

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

scientific article

Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

scientific article

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

scientific article published on 24 June 2019

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

scientific article

Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

scientific article

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia

scientific article published on 09 September 2018

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

scientific article published on 25 February 2015

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

scientific article

Progress in acute myeloid leukemia

scientific article

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

scientific article

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome

scientific article

Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia

scientific article published on 7 April 2016

Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells

scientific article

Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

scientific article published on 19 November 2020

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

scientific article published in January 2003

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

scientific article published on 04 June 2019

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

scientific article

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 16 December 2018

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

scientific article published in March 2003

Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients

scientific article

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

scientific article

Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia

scientific article published in April 2008

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

scientific article published on 26 March 2019

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

scientific article published on 4 January 2017

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

scientific article published on 20 April 2015

Reply to K.R. Hoffman

scientific article published on 14 November 2016

Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options ⬇️

scientific article published on July 26, 2013

Response kinetics and factors predicting survival in core-binding factor leukemia

scientific article published on 08 June 2018

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

scientific article

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase ⬇️

scientific article published on November 15, 2001

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

scientific article published on 13 March 2003

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib

scientific article published in March 2007

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

scientific article published on 14 October 2004

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations

scientific article

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

scientific article

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

scientific article (publication date: August 2003)

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

scientific article published in April 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

scientific article published in June 2003

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

scientific article published on 30 April 2013

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

scientific article

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

scientific article published on 12 April 2018

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

scientific article

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

scientific article published in September 2003

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

scientific article

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies

scientific article published on 11 March 2014

Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment

scientific article published on 19 April 2012

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

scientific article published on 22 March 2016

Rituximab in relapsed or refractory hairy cell leukemia

scientific article

Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on September 2011

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

scientific article

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

scientific article published on 20 March 2003

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

scientific article published on 18 August 2017

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

scientific article published on 18 June 2015

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

scientific article

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

scientific article

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

scientific article

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.

scientific article

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial

scientific article published on 11 September 2018

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

scientific article

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

scientific article

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD

scientific article

Saving Medicare through patient-centered changes--the case of injectables

scientific article published in April 2013

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

scientific article

Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia

scientific article published on May 2007

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

scientific article published on 09 February 2011

Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate

scientific article

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience

scientific article

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review

scientific article published on 24 September 2020

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia

scientific article

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study

scientific article

Sepsis and Acute Myeloid Leukemia: A Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals

scientific article published on 25 July 2017

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse

scientific article

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

scientific article published on 12 September 2013

Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response

scientific article

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

scientific article published in August 2005

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

scientific article published on 4 January 2017

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

scientific article

Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications

scientific article

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

scientific article

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials

scientific article published on 20 September 2013

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

scientific article

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

scientific article published in November 2003

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data

scientific article

Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells

scientific article

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

scientific article published on 31 August 2018

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation

scientific article

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

scientific article published in March 2006

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

scientific article published in August 2010

Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation

scientific article published on 17 July 2006

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

scientific article

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

scientific article published on February 2009

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate

scientific article

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia

scientific article published on 04 October 2019

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

scientific article published in July 2003

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

scientific article published on December 2009

Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience

scientific article

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

scientific article

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

scientific article published in May 2005

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

scientific article

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

scientific article published on 14 July 2020

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

scientific article published on June 2010

Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML

scientific article

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

scientific article published on 05 August 2020

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

scientific article published in July 2008

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

scientific article published in May 2009

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

scientific article

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells

scientific article published on 29 September 2015

Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial

scientific article published on September 2009

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

scientific article published on 8 March 2017

T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.

scientific article published in March 2009

T-cell prolymphocytic leukemia: a single-institution experience

scientific article published on 01 November 2005

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens

scientific article

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

scientific article published on 26 July 2016

Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones

scientific article

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

scientific article published on 24 July 2015

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia

scientific article

Targeted therapy in chronic myeloid leukemia

scientific article published on January 2008

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib

scientific article published on December 2006

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

scientific article

Targeting neuropilin-1 in human leukemia and lymphoma

scientific article

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia

scientific article

Thalidomide therapy for myelofibrosis with myeloid metaplasia

scientific article published on 01 May 2006

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia

scientific article published on 6 September 2013

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

scientific article published on 28 May 2013

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

scientific article

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

scientific article published on 12 November 2020

The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling

scientific article published on 28 April 2014

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

scientific article published on 01 October 2020

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

scientific article published on 20 December 2016

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

scientific article published on 21 November 2017

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure

scientific article

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

scientific article published on 29 July 2011

The biology of chronic myelogenous leukemia: implications for imatinib therapy

scientific article published on January 2007

The changing face of acute myeloid leukemia therapeutics in the elderly population

scientific article published on January 2015

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia

scientific article published on October 2013

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

scientific article published on 10 August 2011

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

scientific article published in July 2005

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

scientific article published on 30 November 2018

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival

scientific article published on 19 November 2019

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

scientific article

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

scientific article

The effects of imatinib on pregnancy outcome

scientific article published on 05 March 2008

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

scientific article

The impact of dasatinib on pregnancy outcomes

scientific article published on 08 September 2015

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

scientific article published on 19 June 2008

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

scientific article

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

scientific article

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients

scientific article

The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors

scientific article published on October 2006

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

scientific article published on 8 January 2009

The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma

scientific article published in May 2002

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

scientific article published on 12 March 2015

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

scientific article published on January 2011

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

scientific article

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

scientific article published on 03 September 2009

The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia ⬇️

scientific article published on September 15, 1995

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

scientific article published on October 2008

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

scientific article

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

scientific article published on July 2008

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

scientific article published on 5 December 2017

Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results

scientific article published on 21 December 2012

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

scientific article

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens

scientific article

Therapy-related myelofibrosis does not appear to exist

scientific article published on 26 May 2017

Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia ⬇️

scientific article published on August 1, 1997

Third-generation tyrosine kinase inhibitors and beyond

scientific article published on October 2010

Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?

scientific article

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

scientific article

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

scientific article published on 14 July 2020

Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia

scientific article published on 09 December 2013

Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review

scientific article published on 30 April 2015

Towards a cure for chronic myeloid leukemia: are we there yet?

scientific article published on October 2010

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

scientific article published on 21 September 2020

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

scientific article published on 19 July 2017

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

scientific article

Treatment of Newly-Diagnosed Acute Promyelocytic Leukemia with Liposomal All-Trans Retinoic Acid ⬇️

scientific article published on July 1, 2001

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

scientific article published on 9 October 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

scientific article published on June 2003

Treatment of Relapsed/Refractory Acute Myeloid Leukemia

scientific article published on March 2017

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine

scientific article

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

scientific article

Treatment options for chronic myeloid leukemia ⬇️

scientific article published on March 19, 2012

Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

scientific article published on 13 August 2019

Treatment selection after imatinib resistance in chronic myeloid leukemia

scientific article published on 30 January 2009

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study

scientific article published on 14 June 2019

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

scientific article

Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.

scientific article published on 26 July 2015

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Treatment-free remission in chronic myeloid leukemia

scientific article published on 01 December 2019

Treatment-free remission with first- and second-generation tyrosine kinase inhibitors

scientific article published on 25 November 2018

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 ⬇️

scientific article published on December 5, 2012

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

scientific article published on 14 February 2006

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

scientific article published on September 2009

Troxacitabine activity in extramedullary myeloid leukemia

scientific article published in June 2002

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation

scientific article published in March 2004

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

scientific article

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

scientific article published on 24 April 2012

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

scientific article

Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY

scientific article published on 31 October 2018

Tyrosine Kinase Inhibitor-associated Fibrothorax

scientific article published on 01 June 2019

Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia

scientific article

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

scientific article

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase

scientific article published on 09 December 2013

Tyrosine kinase inhibitors for chronic myelogenous leukemia.

scientific article published in October 2007

Tyrosine kinase inhibitors in acute and chronic leukemias ⬇️

scientific article published on May 1, 2012

Tyrosine kinase inhibitors: the first decade

scientific article published on April 2010

Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia

scientific article

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

scientific article

Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy

scientific article published in October 2002

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience

scientific article published in May 2003

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm

scientific article published on 24 March 2015

Usefulness of CD11a and CD18 in Flow Cytometric Immunophenotypic Analysis for Diagnosis of Acute Promyelocytic Leukemia ⬇️

scientific article published on 01 November 2012

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics an

scientific article

Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy

scientific article

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

scientific article published on 20 July 2017

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

scientific article published on 30 July 2015

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

scientific article

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia

scientific article

inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases

scientific article

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

scientific article

t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy

scientific article published in April 2006

Paulina is supported by:

About Paulina

Help